VILLANOVA UNIVERSITY — When the FDA approves a new medicine, vaccine, or medical device, there’s a tendency to assume it gets released into the marketplace and reaches those who need it. Professor of Law Ana Santos Rutschman works to illuminate the gap between what should happen and what actually does happen—because, as she notes, “not everyone who needs access gets it.”